Evaluating vaccine effectiveness and determining differences across demographic and clinical risk factors of COVID-19

In a recent study posted to the medRxiv* preprint server, a team of researchers assessed the effectiveness of coronavirus disease 2019 (COVID-19) vaccines against the manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptoms across different cohorts.

Study: Estimating COVID-19 Vaccination Effectiveness Using Electronic Health Records of an Academic Medical Center in Michigan. Image Credit: Dimitris Barletis/ShutterstockStudy: Estimating COVID-19 Vaccination Effectiveness Using Electronic Health Records of an Academic Medical Center in Michigan. Image Credit: Dimitris Barletis/Shutterstock

The unprecedented morbidity and mortality caused by the COVID-19 pandemic have caused a global health crisis. With over 384 million confirmed cases and 5.7 million SARS-CoV-2-related deaths to date, protection provided by COVID-19 vaccines is becoming increasingly crucial. However, the newly emerging SARS-CoV-2 variants of concern (VOCs) have raised doubts over vaccine effectiveness (VE) against these novel strains. Understanding VE across different at-risk populations and the protection provided by the vaccines is instrumental in devising pandemic-control policies.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

About the study

The present study evaluated VE against SARS-CoV-2 infection and assessed if VE was affected by patient characteristics over a period of time across varied demographics.

The study enrolled 170,487 adult patients who were tested for SARS-CoV-2 by six different methods of detection, namely, a commercial polymerase chain reaction (PCR) test; an in-house PCR test; a point of care test with PCR; Quest 37 tests; COVID-19 oropharynx, or nasopharynx PCR tests; and ribonucleic acid (RNA) tests. Among these, 14,059 adults tested SARS-CoV-2-positive while 156,428 samples tested negative for SARS-CoV-2. A total of 74,060 adults were fully vaccinated with either two doses of Moderna or Pfizer BioNTech vaccines or with one dose of Janssen vaccine, at least 21 days before the study began.

Demographic data, including gender, age, race, body mass index (BMI), neighborhood socioeconomic disadvantage index (NDI), and population density, were collected from adults who participated in this study. The Elixhauser comorbidity score was calculated to determine pre-existing comorbidities in COVID-19 patients.

The primary outcomes of the study were susceptibility to COVID-19 infection evaluated by SARS-CoV-2-positive results and severity of symptoms like COVID-19-related hospitalization, intensive care unit (ICU) admission within a month of the latest positive result, or death within two months of testing positive for COVID-19.

Results

The study results showed that 54.2% of the total adults tested for SARS-CoV-2 had been vaccinated with at least one vaccine dose, 43.4% had received at least two vaccine doses. In comparison, only 0.1% of adults were partially vaccinated or were vaccinated with different vaccines. The mean age, number of health care workers, and the Elixhauser score were highest in the fully vaccinated cohort and lowest in the unvaccinated group. Primary care was received by 38.4% of the partially vaccinated group, 44.8% of fully vaccinated adults, and 31.9% of the unvaccinated group.

Among the COVID-positive adults, 12.1% belonged to the unvaccinated group, 6.0% to the partially vaccinated group and 4.7% adults were fully vaccinated. COVID-19 positivity rate reached a plateau at 1.1% among fully vaccinated individuals following low community transmission and surged to 6.7% after approximately eight months, indicating waning VE.

Severe COVID-19-related manifestations like hospitalizations and ICU admissions were observed in 1.4% of the unvaccinated individuals, 0.5% of the partially vaccinated group, and 0.4% of the fully vaccinated cohort. Throughout the year 2021, a severity rate ranging from less than 0.01% to 0.6% was observed in the fully vaccinated group compared to 0.6% to 3.1% in the unvaccinated individuals. Among the fully vaccinated individuals who had received a booster shot, a severity rate of 0.3% was noted.

The VE of a full COVID-19 vaccination against an infection (VE-Susceptibility) ranged from 82.0% to 90.9% in the first half of 2021. However, a reduction in the VE-Susceptibility range to 60.1% to 68.8% was observed in the second half of the year. The VE of a full vaccination against COVID-19 severity (VE-Severity) ranged from 87.4% to 92.2% in the first half of 2021, while an increase from 74.4% to 83.0% was observed in the latter half.

Conclusion

The study findings showed that fully vaccinated individuals were more likely to evade SARS-CoV-2 infection and had a lesser chance of developing severe COVID-19 symptoms than unvaccinated individuals. Also, a waning of VE against infection and disease severity was observed over time across all demographics. However, the administration of booster doses improved VE and lowered infection and disease severity in the boosted group.

Based on the observations, the researchers concluded that COVID-19 vaccines provided sufficient protection against SARS-CoV-2 infection and the severity of the disease. The waning of VE can be improved by administering booster doses across different age groups.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 11 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Susha Cheriyedath

Written by

Susha Cheriyedath

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cheriyedath, Susha. (2023, May 11). Evaluating vaccine effectiveness and determining differences across demographic and clinical risk factors of COVID-19. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20220203/Evaluating-vaccine-effectiveness-and-determining-differences-across-demographic-and-clinical-risk-factors-of-COVID-19.aspx.

  • MLA

    Cheriyedath, Susha. "Evaluating vaccine effectiveness and determining differences across demographic and clinical risk factors of COVID-19". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20220203/Evaluating-vaccine-effectiveness-and-determining-differences-across-demographic-and-clinical-risk-factors-of-COVID-19.aspx>.

  • Chicago

    Cheriyedath, Susha. "Evaluating vaccine effectiveness and determining differences across demographic and clinical risk factors of COVID-19". News-Medical. https://www.news-medical.net/news/20220203/Evaluating-vaccine-effectiveness-and-determining-differences-across-demographic-and-clinical-risk-factors-of-COVID-19.aspx. (accessed November 21, 2024).

  • Harvard

    Cheriyedath, Susha. 2023. Evaluating vaccine effectiveness and determining differences across demographic and clinical risk factors of COVID-19. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20220203/Evaluating-vaccine-effectiveness-and-determining-differences-across-demographic-and-clinical-risk-factors-of-COVID-19.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Futuristic AI-powered virtual lab designs potent SARS-CoV-2 nanobodies